Position
Chief Financial Officer
Company
Kalaris Therapeutics
Berkeley HeightsBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Kalaris Therapeutics, Inc appointed Matthew Gall as Chief Financial Officer and Treasurer, effective November 3, 2025. Mr Gall will also serve as the principal financial officer of the company. He brings extensive experience from his previous role as Chief Financial Officer at iTeos Therapeutics, Inc.
Quick answer
Kalaris Therapeutics Appoints Matthew Gall as Chief Financial Officer (November 3, 2025). Kalaris Therapeutics is based in Berkeley Heights, New Jersey, United States.
- Who is the new Chief Financial Officer at Kalaris Therapeutics?
- Kalaris Therapeutics named Matthew Gall Chief Financial Officer, announced November 3, 2025.
- What did Kalaris Therapeutics announce on November 3, 2025?
- Kalaris Therapeutics, Inc appointed Matthew Gall as Chief Financial Officer and Treasurer, effective November 3, 2025. Mr Gall will also serve as the principal financial officer of the company.
- What does Kalaris Therapeutics do?
- Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs.
- Where is Kalaris Therapeutics based?
- Kalaris Therapeutics is based in Berkeley Heights, New Jersey, United States.
- Which similar companies made leadership changes around the same time?
- Atossa Therapeutics (October 14, 2025), VistaGen (December 1, 2025), Jubilant Therapeutics (December 2, 2025) and Centessa Pharmaceuticals plc (December 12, 2025) also announced leadership changes within 45 days of Kalaris Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in Therapeutics and Pharmaceutical
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Atossa Therapeutics Appoints Mark Daniel as Chief Financial Officer (October 14, 2025)
- Vistagen Appoints Nick Tressler as Chief Financial Officer (December 1, 2025)
- Jubilant Pharmova Appoints Daniel J. O’Connor as Chief Executive Officer (December 2, 2025)
- Centessa Pharmaceuticals Appoints Mario Alberto Accardi as CEO (December 12, 2025)
- Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer (November 4, 2025)
- Esperion Appoints John Harlow as Chief Commercial Officer (November 4, 2025)
Who to call at Kalaris Therapeutics, and when
A new leader at Kalaris Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Kalaris Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kalaris Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kalaris Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kalaris Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Kalaris Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.